AEZS's Diagnostic Test:Just listening to some old AEZS's presentations on YouTube and one analyst had a US$40-US$70 million estimate for revenue many years ago. Significant pricing flexibility was expected for children given the Orphan Drug Designation. 90% of Novo Nordisk's drug sales for growth hormone deficiency were in the childhood market. That might help explain why Novo Nordisk dropped the test. AEZS's test wasnt' approved for children and the childhood trial was significantly delayed due to COVID and Putin's invasion of Ukraine. The trial was expected to take place, in part, in Russia. In 2024 AEZS is finally expected to receive FDA approval for the childhood market. Children are the key market for growth hormone deficiency. How about relicensing it to Novo Nordisk with approval now for children.